The results demonstrated that cisatracurium besilate enhanced the TRAIL-induced apoptosis of GC cells via p53 signaling, suggesting that cisatracurium besilate increased the sensitivity of TRAIL to amplify the therapeutic efficacy of itself in GC management. This evidence concerns the gene TP53 and gastric cancer.